chartexchange

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

The Motley Fool | Nov 9, 2026 3:18 PM EST

On paper, Monday was a good day in many ways for ImmunityBio (NASDAQ:IBRX) . The company reported that sales of ANKTIVA, its bladder-cancer immunotherapy, rose 53% from a year earlier to $48.7 million in the third quarter. It also said a randomized trial of ANKTIVA in patients new to BCG treatment met its main goal. Despite those results, the stock fell about 15% anyway to around $7.30 in late-afternoon trading. It has still more than tripled this year, from $2 at the end of 2025, though it sits about 40% below its February high of $12.43. So what is the market telling investors? Image source: Getty Images. Continue reading

Read original article